Brief: Oxigene says U.S. FDA approved protocol for focus, phase 2/3 study of ca4p for the treatment of platinum-resistant ovarian cancer

Oncotelic Therapeutics

03/02/2016 14:01

Feb 3 (Reuters) - OXiGENE Inc  OXGN.O : 
 * Says U.S. FDA approved protocol for focus, phase 2/3 study of ca4p for the 
   treatment of platinum-resistant ovarian cancer 
 * Focus will test whether ca4p improves progression-free survival when combined 
   with bevacizumab and chemotherapy 
 * Says if the trial is successful, data from focus would be used as the basis 
   for a new drug application to the FDA 
 
* Source text for Eikon  urn:newsml:reuters.com:*:nGNXMMEZRa 
 
* Further company coverage  OXGN.O  ((Bengaluru Newsroom; +1 646 223 8780))